Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + lenalidomide + dexamethasone after injectable PI in relapsed/refractory multiple myeloma
jRCT1080223783Phase 4Completed
- Sponsor
- Takeda
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixazomib in multiple myeloma (MM), sponsored by Takeda. Started Jan 2018; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT1080223783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223783.